[Anticancer effect of peplomycin on advanced recurrent breast cancer].
The anticancer effect of peplomycin (PEP) on advanced or recurrent breast cancer was investigated clinically and histopathologically. Stage III (n = 12), Stage IV (n = 2) and recurrent (n = 6) breast cancer patients were treated with PEP of which 10 mg were administered 3 times a week for 3 weeks either intravenously (n = 13) or intra-arterially (n = 7, via a catheter inserted into the subclavian artery). A decrease in tumor volume of more than 50% was obtained in 38.5% of the intravenously treated cases and in 28.6% the intra-arterially treated cases. Histologically, grades II b and III were observed in 66% of patients according to Oboshi's classification. These investigations suggest the effectiveness of PEP on breast cancer.
D000328:Adult; D000368:Aged; D001761:Bleomycin / Q000008:administration & dosage / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D007269:Injections, Intra-Arterial; D007275:Injections, Intravenous; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D017663:Peplomycin
D001761:Bleomycin; D017663:Peplomycin